

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809761
Filing Date	March 25, 2004
First Named Inventor	Charles R. Stewart
Art Unit	1653
Examiner Name	Suzanne Marie Mayer
Attorney Docket Number	61683-00004USPT

Sheet

3

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SMN	C 16	SHAMOO, Y. et al., Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 A resolution, Nature Structural Biology, Mar. 1997, pp. 215-222, Vol. 4(3).	
SMN	C 17	ZHANG, H. et al., New Perspectives on Anti-HER2/Neu Therapeutics, Drug News Perspect, Aug. 2000, pp. 325-9, Vol. 13(6). August 2000	

Examiner Signature	/Suzanne Noakes/	Date Considered	08/09/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/B/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/809761		
		Filing Date	March 25, 2004		
		First Named Inventor	Charles R. Stewart		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	61683-00004USPT

SMN	30	Spee J.H., et al. (1993) Nucleic Acids Res. 21:777-778	
	31	Smith, R.A., et al. (2001) Bioorganic and Medical Chemistry Letters 11: 2951-4	
	32	Stewart, C.R. (1993) in <i>Bacillus subtilis</i> and other gram-positive bacteria (A. Sonenshein, J.A. Hoch, and R. Losick, eds. American Society for Microbiology) pp. 813-829	
	33	Stewart C.R., et al. (1998) Virology 246:329-340	
	34	Stewart C.R. (1999) SPO1 Phage (Myoviridae), in Encyclopedia of Virology (2nd Edition, Webster, R.G., and Granoff, A., eds.) pp. 1681-1685	
	35	Stewart, C.R. et al. (Aug. 8-13, 2001) In Abstracts of the Fourteenth Evergreen International Phage Biology Meeting.	
	36	Tatusova, T.A. & T.L. Madden (1999) FEMS Microbiol. Lett. 174: 247-50.	
	37	Tian S.S., et al. (1998) Science 281:257-259	
	38	Vandeyar, M.A., and S. A. Zahler (1986) J. Bacteriol. 167: 530-4.	
	39	Wanner, B.L. (1986) J. Mol. Biol. 191: 39-58.	
	40	Wei P. & Stewart C.R. (1993) A cytotoxic early gene of <i>Bacillus subtilis</i> bacteriophage SPO1. J Bacteriol. 175(24):7887-900	
	41	Wei P. & Stewart C.R. (1995) Genes that protect against the host-killing activity of the E3 protein of <i>Bacillus subtilis</i> bacteriophage SPO1, J. Bacteriol. 177, 2933-2937	
	42	Willats, W.G.T. (2002) Plant Molecular Biology 50: 837-54.	
	43	Wrighton, N., and D. Gearing (1999) Nature Biotech. 17: 1157-8.	
	44	Duckworth, D. et al., "Bacteriophages: potential treatment for bacterial infections", BioDrugs 2002;16(1):57-62	
	45	Cudic, M. et al., "Intracellular targets of antibacterial peptides", Curr Drug Targets 2002 Apr;3(2):101-6.	
V	46	Sadler, K. et al., "Translocating proline-rich peptides from the antimicrobial peptide bacteriocin 7", Biochemistry 2002 Dec 3;41(48):14150-7.	
SMN	47	Kutter E., "Phage Therapy: Bacteriophages as Antibiotics" November 1997 <a href="http://www.evergreen.edu/phage/phagetherapy.html">http://www.evergreen.edu/phage/phagetherapy.html</a> , page 1-24	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

/Suzanne Noakes/

08/09/2006

Examiner Signature	<i>Suzanne M Noakes</i>	Date Considered	8/9/2006
--------------------	-------------------------	-----------------	----------

HOUSTON 314631v1 61683-00004USPT